PT - JOURNAL ARTICLE AU - Sheila K. Pirooznia AU - Liana S. Rosenthal AU - Valina L. Dawson AU - Ted M. Dawson ED - Barker, Eric TI - Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection AID - 10.1124/pharmrev.120.000189 DP - 2021 Oct 01 TA - Pharmacological Reviews PG - 1204--1268 VI - 73 IP - 4 4099 - http://pharmrev.aspetjournals.org/content/73/4/1204.short 4100 - http://pharmrev.aspetjournals.org/content/73/4/1204.full SO - Pharmacol Rev2021 Oct 01; 73 AB - Parkinson disease (PD) used to be considered a nongenetic condition. However, the identification of several autosomal dominant and recessive mutations linked to monogenic PD has changed this view. Clinically manifest PD is then thought to occur through a complex interplay between genetic mutations, many of which have incomplete penetrance, and environmental factors, both neuroprotective and increasing susceptibility, which variably interact to reach a threshold over which PD becomes clinically manifested. Functional studies of PD gene products have identified many cellular and molecular pathways, providing crucial insights into the nature and causes of PD. PD originates from multiple causes and a range of pathogenic processes at play, ultimately culminating in nigral dopaminergic loss and motor dysfunction. An in-depth understanding of these complex and possibly convergent pathways will pave the way for therapeutic approaches to alleviate the disease symptoms and neuroprotective strategies to prevent disease manifestations. This review is aimed at providing a comprehensive understanding of advances made in PD research based on leveraging genetic insights into the pathogenesis of PD. It further discusses novel perspectives to facilitate identification of critical molecular pathways that are central to neurodegeneration that hold the potential to develop neuroprotective and/or neurorestorative therapeutic strategies for PD.Significance Statement A comprehensive review of PD pathophysiology is provided on the complex interplay of genetic and environmental factors and biologic processes that contribute to PD pathogenesis. This knowledge identifies new targets that could be leveraged into disease-modifying therapies to prevent or slow neurodegeneration in PD.